Introduction. Asymmetric dimethylarginine (ADMA) is a nonselective nitric oxide (NO) synthase inhibitor associated with cardiovascular and metabolic disorders. ADMA plays an important role in the regulation of vascular tone by acting as an endogenous inhibitor of NO synthesis. Objectives. This study aimed to investigate ADMA with respect to diabetes and its clinical relevance as an independent predictor of CAD (Coronary Artery Disease). Methodology. The present case control study includes two hundred and forty patients selected randomly. Serum ADMA was analyzed by using enzyme immunoassay for the quantitative determination of endogenous ADMA, and serum nitric oxide was estimated by the method of Cortes. Results. Elevated NO level levels was a strong predictor and significantly (t: 9.86, P < 0.001) associated with occurrence of CAD. Increased ADMA level was found to be another strong predictor and associated significantly (t: 8.02, P < 0.001) with CAD. On intra group analysis, the relationship between ADMA and NO in diseased group, is significant negative correlation (r = −0.743). P (0.001) was found between ADMA and NO. Conclusion. ADMA level was found to be one of the strong predictors for CAD. ADMA is an emerging independent risk marker for future CVD (cardiovascular disease) events.

No abstract

No abstract

No abstract

Introduction: Diabetes mellitus is a metabolic disease known by chronic hyperglycemia which results from defective insulin action and secretion. Metabolic syndrome consists of a constellation of metabolic abnormalities that confer increased risk of diabetes mellitus. The aim of the present study was to study BMI and lipid profile in patients with metabolic syndrome and type 2 diabetes mellitus. Materials and methods: 50 controls, 50 individuals with metabolic syndrome and 50 individuals with type 2 diabetes mellitus were selected by purposive sampling technique. BMI was calculated and serum levels of cholesterol, triglycerides, LDL, VLDL and HDL were estimated in controls and cases. Results: BMI, serum triglycerides, VLDL, cholesterol/HDL ratio were significantly increased (p<0.05) and serum HDL levels were significantly decreased (p<0.05) in metabolic syndrome and type 2 diabetes compared to controls. Conclusion: Our study concluded that there is significant dyslipidemia in patients with metabolic syndrome and type 2 diabetes mellitus.